抗凝治疗慢性心衰房颤患者失代偿期临床研究

摘要

ObjectiveTo investigate clinical effect by anticoagulation therapy for decompensated chronic heart failure and auricular fibrillation patients.MethodsA total of 161 chronic heart failure and auricular fibrillation patients were randomly divided into control group (80 cases, received conventional treatment for anti-heart failure) and experimental group (81 cases, received additional anticoagulation therapy). Treatment status of the two groups were compared and analyzed. Clinical effect was analyzed.ResultsThe experimental group had higher total effective rate than the control group (P<0.05). There were 42 cases with N-terminal pro-brain natriuretic peptide (NT-proBNP) ≥300 ng/L and 39 cases with NT-proBNP <300 ng/L in the experimental group. The control group had 29 cases with NT-proBNP ≥300 ng/L and 51 cases with NT-proBNP <300 ng/L. The difference between the two groups had statistical significance (P<0.05).ConclusionAnticoagulation therapy contains important clinical significance for decompensated chronic heart failure and auricular fibrillation patients. This method can effectively improve curative effect and reduce hospital stay. It is worthy of wide promotion.%目的：探讨抗凝治疗慢性心力衰竭(简称心衰)心房颤动(简称房颤)患者失代偿期的临床疗效。方法161例慢性心衰房颤患者，随机分为对照组(80例，给予普通抗心衰治疗)和实验组(81例，在对照组基础上给予抗凝治疗)。对比分析两组患者的临床疗效。结果实验组的总有效率高于对照组(P<0.05)；实验组N末端脑钠肽前体(NT-proBNP)≥300 ng/L患者42例，<300 ng/L患者39例，对照组≥300 ng/L患者29例，<300 ng/L患者51例，两组比较，差异具有统计学意义(P<0.05)。结论抗凝治疗对于慢性心衰房颤患者失代偿期具有重要临床意义，可明显提高治疗效果，减少住院时间，值得广泛推广。